A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
Alessandro M. Vannucchi(Azienda Ospedaliero-Universitaria Careggi), F. Cervantes(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Abdel Hmissi(Centre Hospitalier René-Dubos), Nicholas J. Sarlis(Incyte (United States)), Ruben A. Mesa(Atrium Health Wake Forest Baptist), Viktoriya Stalbovskaya(Novartis (Switzerland)), Claire Harrison(Guy's and St Thomas' NHS Foundation Trust), P. Gopalakrishna(Novartis (Switzerland)), Wei Peng(Incyte (United States)), Jason Gotlib(Stanford University), Vikas Gupta(Indian Institute of Technology Kanpur), Srđan Verstovšek(Unknown), H. Kantarjian(The University of Texas MD Anderson Cancer Center), Jean‐Jacques Kiladjian(Délégation Paris 5), V. Sandor(Incyte (United States))
Cited by 252
Related Papers
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>
|New England Journal of Medicine|2013|1.7k